Literature DB >> 18207685

Clinical implication of F-18 FDG PET/CT for differentiated thyroid cancer in patients with negative diagnostic iodine-123 scan and elevated thyroglobulin.

Seong-Jang Kim1, Tae Hong Lee, In-Ju Kim, Yong-Ki Kim.   

Abstract

UNLABELLED: This study aims to investigate the usefulness of F-18 FDG PET/CT in differentiated thyroid cancer (DTC) with elevated serum thyroglobulin (Tg) but negative iodine-123 (I-123) scan.
METHODS: Twenty patients with histopathologically proven DTC, negative diagnostic I-123 scan, and elevated serum Tg levels were prospectively submitted to F-18 FDG PET/CT evaluation. The histopathologic findings consisted of 19 papillary thyroid cancers, 1 follicular thyroid cancer.
RESULTS: F-18 FDG PET/CT identified lesions in 18 out of 20 patients, giving a sensitivity of 90%. Thirteen of the 18 patients revealed limited loco-regional disease. Remaining 5 patients showed distant metastases, consisting of 4 patients with lung metastases and 1 patient with bone metastasis. Two patients revealed negative F-18 FDG PET/CT findings.
CONCLUSION: F-18 FDG PET/CT is suitable for the detection and precise localization of loco-regional recurrences and distant metastases of DTC in patients with elevated serum Tg but negative I-123 whole body scan.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18207685     DOI: 10.1016/j.ejrad.2007.12.004

Source DB:  PubMed          Journal:  Eur J Radiol        ISSN: 0720-048X            Impact factor:   3.528


  6 in total

1.  American Thyroid Association statement on preoperative imaging for thyroid cancer surgery.

Authors:  Michael W Yeh; Andrew J Bauer; Victor A Bernet; Robert L Ferris; Laurie A Loevner; Susan J Mandel; Lisa A Orloff; Gregory W Randolph; David L Steward
Journal:  Thyroid       Date:  2015-01       Impact factor: 6.568

2.  [18F]-FDG-PET/CT and [18F]-FAZA-PET/CT Hypoxia Imaging of Metastatic Thyroid Cancer: Association with Short-Term Progression After Radioiodine Therapy.

Authors:  Masatoyo Nakajo; Megumi Jinguji; Atsushi Tani; Yoriko Kajiya; Tooru Nandate; Ikumi Kitazano; Takashi Yoshiura
Journal:  Mol Imaging Biol       Date:  2020-12       Impact factor: 3.488

3.  Positron Emission Tomography (PET) and PET/CT in Thyroid Cancer: A Systematic Review and Meta-Analysis.

Authors:  Friederike Schütz; Christine Lautenschläger; Kerstin Lorenz; Johannes Haerting
Journal:  Eur Thyroid J       Date:  2017-10-24

4.  Impact of combined FDG-PET/CT and MRI on the detection of local recurrence and nodal metastases in thyroid cancer.

Authors:  Johann-Martin Hempel; Roman Kloeckner; Sandra Krick; Daniel Pinto Dos Santos; Simin Schadmand-Fischer; Patrick Boeßert; Sotirios Bisdas; Matthias M Weber; Christian Fottner; Thomas J Musholt; Mathias Schreckenberger; Matthias Miederer
Journal:  Cancer Imaging       Date:  2016-11-03       Impact factor: 3.909

5.  Fluorodeoxyglucose-positron emission tomography scan-positive recurrent papillary thyroid cancer and the prognosis and implications for surgical management.

Authors:  Jennifer M J Schreinemakers; Menno R Vriens; Nuria Munoz-Perez; Marlon A Guerrero; Insoo Suh; Inne H M Borel Rinkes; Jessica Gosnell; Wen T Shen; Orlo H Clark; Quan-Yang Duh
Journal:  World J Surg Oncol       Date:  2012-09-17       Impact factor: 2.754

6.  Usefulness of PET/CT in the diagnosis of recurrent or metastasized differentiated thyroid carcinoma.

Authors:  Cun-Zhi Lu; Su-Sheng Cao; Wei Wang; Jun Liu; Ning Fu; Feng Lu
Journal:  Oncol Lett       Date:  2016-02-15       Impact factor: 2.967

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.